Stereotaxis Completes Installation of the World’s 1st Genesis Robotic Magnetic Navigation Systems to Treat Heart Rhythm Disorders at Helsinki University Hospital in Finland and Banner – University Medicine Heart Institute in Phoenix, Arizona

Stereotaxis today announced it has completed installations of the world’s first Genesis Robotic Magnetic Navigation systems to treat heart rhythm disorders at Helsinki University Hospital in Finland and Banner – University Medicine Heart Institute in Phoenix, Arizona.

“The clinical benefits of robotics in electrophysiology have been extensively documented at our hospital over many years,” said Dr. Pekka Raatikainen, Chief of Electrophysiology and Pacing at the Heart and Lung Center at Helsinki University Central Hospital. “With the adoption of the first Genesis systems in the world, we are proud to be a pioneer in the process of advancing robotic technology for the benefits of patients and the medical community.”

“The capabilities of robotics are growing at a rapid rate, moving us toward a paradigm shift in our practice,” said Dr. J. Peter Weiss, Director of Ventricular Arrhythmia Management and Robotics at Banner – University Medicine Heart Institute. “I am extremely excited to play a part in bringing this advanced technology to our community of patients and heart rhythm specialists throughout Phoenix and beyond.”

Stereotaxis notes the Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias, abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, certain arrhythmias can significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. The Genesis RMN® system provides the established benefits and reliability of RMN in a highly innovative architecture that is faster, smaller, lighter, and more flexible. Adopting the Genesis RMN system reflects a commitment to using the most advanced technologies to enhance patient care.

“Patients with medical conditions from the most complex to the most common seek us out for care in part because we remain on the cutting edge in technology and safety,” said Kristi McShay, Assistant Vice President for the Cardiovascular Line at Banner Health. “We are pleased to be the first in the nation to offer this new generation of robotics for treating heart rhythm disorders.”

“This technology allows us to positively address the increasing number of patients with complex arrhythmias. In addition, it provides us a competitive advantage to other Nordic centers concerning education and learning,” said Antti Vento, Medical Director of Helsinki Heart and Lung Center.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.